Evidence map›Paper›PMID 41940985›Full record

ArticleAnnals of hematology2026

Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials.

Antonella Bruzzese, Danilo Lofaro, Enrica Antonia Martino, Francesco Mendicino, Caterina Labanca, Santino Caserta, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Fortunato Morabito and 2 more

Abstract readNetwork Meta-AnalysisComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Antonella BruzzeseHematology Unit, Department of Onco-Hematology, AO of Cosenza, Viale Della Repubblica Snc, 87100, Cosenza, Italy.
Danilo LofaroDepartment of Mathematics and Computer Science, University of Calabria, 87036, Rende, Italy.
Enrica Antonia MartinoHematology Unit, Department of Onco-Hematology, AO of Cosenza, Viale Della Repubblica Snc, 87100, Cosenza, Italy.
Francesco MendicinoHematology Unit, Department of Onco-Hematology, AO of Cosenza, Viale Della Repubblica Snc, 87100, Cosenza, Italy.
Caterina LabancaHematology Unit, Department of Onco-Hematology, AO of Cosenza, Viale Della Repubblica Snc, 87100, Cosenza, Italy.
Santino CasertaHematology Unit, Department of Onco-Hematology, AO of Cosenza, Viale Della Repubblica Snc, 87100, Cosenza, Italy.
Eugenio LuciaHematology Unit, Department of Onco-Hematology, AO of Cosenza, Viale Della Repubblica Snc, 87100, Cosenza, Italy.
Virginia OlivitoHematology Unit, Department of Onco-Hematology, AO of Cosenza, Viale Della Repubblica Snc, 87100, Cosenza, Italy.
Nicola AmodioDepartment of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
Fortunato MorabitoAIL Sezione Di Cosenza, Cosenza, Italy.
Ernesto VignaHematology Unit, Department of Onco-Hematology, AO of Cosenza, Viale Della Repubblica Snc, 87100, Cosenza, Italy. ernesto.vigna@aocs.it.
Massimo GentileHematology Unit, Department of Onco-Hematology, AO of Cosenza, Viale Della Repubblica Snc, 87100, Cosenza, Italy. massimo.gentile@unical.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FLT3-mutated acute myeloid leukemia (FLT3mut AML) is associated with poor outcomes. Although FLT3 inhibitors (FLT3is) combined with chemotherapy improve responses, long-term survival remains limited, and the optimal first-line strategy is unclear. We conducted a Bayesian network meta-analysis of eight randomized trials, including 1,793 patients, to compare treatment used in patietne eligible for intensive chemoteherapy for overall survival (OS). Treatments studied were 3 + 7 with midostaurin, quizartinib, sorafenib, gemtuzumab ozogamicin (GO), glasdegib, CPX-351, and decitabine. FLT3i-based regimens improved outcomes but showed attenuated effects in this analysis, consistent with prior data. The small population with FLT3 mutation treated with GO + 3 + 7 and CPX-351 provided good outcomes (SUCRA 86.1% and 71.7%), while glasdegib + 3 + 7 and decitabine resulted in less effective strategies. Notably, 3 + 7 + GO showed superior benefit despite limited FLT3mut subgroup evidence. Ongoing studies are exploring CPX-351, GO, and FLT3i combinations, as well as novel strategies. Prospective, mutation-specific trials are needed to define optimal therapy.

Indexed as

Antineoplastic Combined Chemotherapy Protocolsfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationBayes TheoremBenzothiazolesCytarabineDaunorubicinDecitabineGemtuzumabHumansPhenylurea CompoundsProtein Kinase InhibitorsRandomized Controlled Trials as TopicSorafenibStaurosporineBenzothiazolesCPX-351CytarabineDaunorubicinDecitabineFLT3 protein, humanfms-Like Tyrosine Kinase 3GemtuzumabPhenylurea CompoundsProtein Kinase InhibitorsquizartinibSorafenibStaurosporineFLT3mutated (FLT3mut) AMLMeta-analysisOS in AMLTreatment naïve AML

Identifiers

PMID41940985
PMCPMC13053374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.